RxDoctor Payments DataLook up a doctor →

Richard Furie, MD

Rheumatology · New Hyde Park, NYNPI 1538175740

Payments from drug & device makers

$4,296,081in general payments, 2019–2025

Across 736 payments — averaging $5837.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1.8M
  • Genentech, Inc.$576K
  • AstraZeneca$273K
  • Astrazeneca UK Limited$264K
  • Hoffmann-la Roche Limited$229K
  • GSK$192K
  • plus $981K from 37 others
$40,465in research payments, 2019–2025

Across 32 payments — averaging $1264.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • F. Hoffmann-la Roche AG$14K
  • Takeda Pharmaceuticals U.S.A., Inc.$8K
  • UCB, Inc.$6K
  • Biogen$6K
  • AbbVie$3K
  • Eli Lilly$2K
  • plus $2K from 1 others

What the payments were for

  • Consulting fees$514,69869%
  • Speaking & faculty fees$124,08317%
  • Grants$4,1461%
  • Travel & lodging$95,43113%
  • Food & beverage$6,4551%
  • Education$1,0070%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,296,081 in reported general payments places this provider in the 95th percentile of 541 rheumatology providers in New York.

See all rheumatology providers in New York

Medicare billing

Part B allowed, 2024
$6,348,863
Medicare patients
475
Services billed
228,975

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib35$211,188
Humira(Cf) PenAdalimumab13$136,316
Enbrel SureclickEtanercept17$119,330
Mycophenolate Mofetil59$8,682
Hydroxychloroquine Sulfate165$6,025
MethotrexateMethotrexate Sodium129$3,863
Prednisone154$1,280
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen47$969
Nifedipine ErNifedipine18$700
Warfarin Sodium38$676
Celecoxib19$593
Methylprednisolone25$586
Azathioprine11$511
ValacyclovirValacyclovir Hcl12$348
Gabapentin14$313

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$2,857$211,18835 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 541 rheumatology providers in New York.

Other rheumatology in New Hyde Park

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →